Biomarkers identified for cytokine release syndrome risk after CAR T-cell therapy
For patients with autoimmune disease, higher baseline B-cell counts and systemic inflammation are associated with development of cytokine release syndrome (CRS) after chimeric antigen receptor (CAR) T-cell therapy, according to a study published in the November issue of The Lancet Rheumatology.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Smart probe makes aggressive breast cancer cells glow during surgery
United Kingdom
-
Immunotherapy combo extends survival for patients with aggressive small cell lung cancer, based on trial results
United Kingdom
-
Physical activity may help lower genetic risk of depression in adults
United Kingdom
-
KAIST team develops neural chip to track Alzheimer's drug response
United Kingdom
-
Florida dengue cases nearly double a month after emergency declared
United Kingdom
-
AI chatbots may worsen symptoms in people with psychosis
United Kingdom
-
Simple drug adjustment reduces kidney damage during septic shock surgery
United Kingdom
-
AI chatbots can be a valuable health resource for older adults—if they embrace 'informed skepticism'
United Kingdom